Literature DB >> 2316228

Characterization of dexamethasone binding in normal and uremic human serum.

D M Cummings1, G E Larijani, D P Conner, R K Ferguson, M L Rocci.   

Abstract

The purpose of this study was to examine the extent and linearity of dexamethasone binding over a wide concentration range in normal and uremic serum. Tritiated dexamethasone was added to both untreated and charcoal-treated pooled normal serum and to pooled uremic serum to produce concentrations similar to those attained therapeutically (10-1000 ng/mL). Protein binding was determined by equilibrium dialysis at 37 degrees C. Dexamethasone serum binding was linear over the entire range of concentrations for each set of pooled serum. The mean (+/- SD) percent bound (mean +/- SD) for dexamethasone was similar for untreated (75.1 +/- 3.6 percent) and charcoal-treated (77.3 +/- 3.5 percent) normal serum. Dexamethasone binding (69.2 +/- 1.8 percent, p less than 0.05) and serum albumin concentrations (39.9 vs. 55.1 mmol/L) were significantly less in uremic vs. normal serum, respectively. These results suggest that (1) the binding of dexamethasone is linear and occurs primarily to albumin, with little or no binding to corticosteroid-binding globulin; (2) endogenous cortisol does not compete with dexamethasone for protein binding sites; and (3) steroid pharmacokinetics may be altered in uremic patients due to the 24 percent higher free fraction of dexamethasone in this population.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2316228     DOI: 10.1177/106002809002400301

Source DB:  PubMed          Journal:  DICP        ISSN: 1042-9611


  6 in total

Review 1.  Clinical Relevance of Steroid Use in Neuro-Oncology.

Authors:  K Ina Ly; Patrick Y Wen
Journal:  Curr Neurol Neurosci Rep       Date:  2017-01       Impact factor: 5.081

Review 2.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Modeling Combined Immunosuppressive and Anti-inflammatory Effects of Dexamethasone and Naproxen in Rats Predicts the Steroid-Sparing Potential of Naproxen.

Authors:  Xiaonan Li; Debra C DuBois; Dawei Song; Richard R Almon; William J Jusko; Xijing Chen
Journal:  Drug Metab Dispos       Date:  2017-04-17       Impact factor: 3.922

Review 4.  Demographics, assessment and management of pain in the elderly.

Authors:  Mellar P Davis; Manish Srivastava
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

5.  Dexamethasone does not diminish sugammadex reversal of neuromuscular block - clinical study in surgical patients undergoing general anesthesia.

Authors:  Katja Rezonja; Tomaz Mars; Ales Jerin; Gordana Kozelj; Neva Pozar-Lukanovic; Maja Sostaric
Journal:  BMC Anesthesiol       Date:  2016-10-21       Impact factor: 2.217

Review 6.  Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment.

Authors:  Fiona Marra; Elise J Smolders; Omar El-Sherif; Alison Boyle; Katherine Davidson; Andrew J Sommerville; Catia Marzolini; Marco Siccardi; David Burger; Sara Gibbons; Saye Khoo; David Back
Journal:  Drugs R D       Date:  2020-12-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.